文献速递骨质疏松与代谢性骨病创伤骨科

地舒单抗与男性骨质疏松症患者的临床结局:一项回顾性队列研究

Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study.
PubMed 文献 · Osteoporos Int · 2025-01-08

本研究基于台湾全民健康保险研究数据库,纳入13,797名≥50岁接受地舒单抗治疗的男性骨质疏松症患者,比较持续治疗(每6个月皮下注射60 mg)与仅一次给药后停药者的临床骨折发生率。经倾向评分逆概率治疗加权后,持续治疗组髋部骨折风险较停药组降低36%(HR 0.64,95%CI 0.50-0.83),临床椎体和非椎体骨折也观察到相似幅度的风险降低。

要点

  • 男性骨质疏松症患者持续使用地舒单抗与髋部骨折风险降低36%相关(HR 0.64,95%CI 0.50-0.83)。
  • 临床椎体和非椎体骨折也观察到与髋部骨折相似幅度的风险降低。
  • 该真实世界研究结果与女性绝经后骨质疏松症临床试验中观察到的风险降低一致。

核心结论

  • 在这项评估男性骨质疏松症患者地舒单抗治疗的大型真实世界研究中,观察到的骨折风险降低与女性绝经后骨质疏松症临床试验中已证实的风险降低一致。

研究设计与样本

  • 回顾性队列研究,纳入台湾13,797名年龄≥50岁、已启动地舒单抗治疗的男性骨质疏松症患者,数据来源于台湾全民健康保险研究数据库。
  • 比较持续治疗(每6个月皮下注射地舒单抗60 mg)与仅一次给药后停药患者的临床骨折发生率,采用倾向评分分析和Cox比例风险模型估计校正风险比。

主要发现

  • 随访期间共发生248例髋部骨折事件。
  • 持续治疗组髋部骨折粗发生率为每100人年1.13例,停药组为每100人年1.73例。
  • 经倾向评分逆概率治疗加权后,全部59个协变量达到均衡。
  • 持续治疗组髋部骨折事件率较停药组降低36%(风险比0.64,95%CI 0.50-0.83)。
  • 临床椎体和非椎体骨折也观察到相似幅度的风险降低。

关键数值与推荐

  • 持续治疗组髋部骨折粗发生率每100人年1.13例 vs 停药组每100人年1.73例。
  • 持续治疗组较停药组髋部骨折风险降低36%(HR 0.64,95%CI 0.50-0.83)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Most subjects in osteoporosis clinical trials were women with postmenopausal osteoporosis and while bridging studies (BMD endpoint) provide an expectation that osteoporosis medications will reduce fracture risk in men. This real-world study shows direct evidence of fracture risk reduction among men with osteoporosis (36% of hip fracture reduction with denosumab). PURPOSE: Direct evidence for fracture risk reduction of medications used among men with osteoporosis is very limited. This study aims to evaluate the real-world effectiveness of denosumab in reducing fracture risk. METHODS: This study included 13,797 men aged ≥ 50 years with osteoporosis who had initiated denosumab in Taiwan. Taiwan's National Health Insurance Research Database includes all Taiwan residents' complete health claim data. We compared incidence rates of clinical fractures between patients on denosumab 60 mg subcutaneously every 6 months (on-treatment) and patients ending therapy after one administration (off-treatment). Propensity score (PS) analysis, adjusting for measured differences at baseline covariates, was used to estimate the adjusted hazard ratio using a Cox proportion hazards model. RESULTS: During follow-up, 248 hip fracture events occurred. The crude incidence rates of hip fracture were 1.13 events and 1.73 events per 100 person-years in on-treatment and off-treatment cohorts, respectively. After PS inverse probability of treatment weighting, the cohorts achieved balance in all 59 covariates. The hip fracture event rate was lower in on-treatment cohort versus off-treatment cohort by 36% (hazard ratio, 0.64 [95% CI 0.50-0.83]). A similar magnitude of risk reduction was observed in clinical vertebral and nonvertebral fractures. A series of sensitivity analysis, including a validation analysis using a-million individual health records, demonstrated that unmeasured confounders were not suggested to impact study result interpretation. CONCLUSION: In this large, real-world study evaluating denosumab treatment among men with osteoporosis, the observed fracture risk reductions were consistent with the available risk reductions demonstrated in clinical trials among women with postmenopausal osteoporosis.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Huang Z, Liao TC, Chuang AT, et al. Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study. Osteoporos Int. 2025. PMID: 39777487. doi:10.1007/s00198-024-07381-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。